{
    "nctId": "NCT02201381",
    "briefTitle": "Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer",
    "officialTitle": "A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Matched Controls",
    "overallStatus": "WITHDRAWN",
    "conditions": "Cancer, Overall Survival",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Overall survival",
    "eligibilityCriteria": "Inclusion criteria\n\n1. Male or female 18-85 years old;\n2. Diagnosed with cancer and have had such diagnosis confirmed by scan, blood markers and/or biopsy;\n3. Is receiving or will shortly receive standard of care therapy or has completed standard of care treatment; and\n4. Signed and dated written informed consent from the participant or LAR.\n\nExclusion Criteria:\n\n1. Pregnant or lactating females or females who are planning a pregnancy during the course of the study;\n2. Major organ failure, renal, lung and liver failure;\n3. Participants having active liver disease or unexplained persistent elevation of serum transaminases \\> 3 times the upper limit of normal;\n4. Participants with diabetic ketoacidosis or diabetic pre-coma;\n5. Participants with a creatinine clearance \\< 60mL/min;\n6. History of cardiac or respiratory failure;\n7. History of recent myocardial infarction;\n8. Ileum, colon or stomach part or full removal rendering them unable to take the study medicines;\n9. Unable to eat or keep food or medicines down or is being fed intravenously;\n10. Is too frail and weak to withstand the study medicines in the opinion of the study doctor;\n11. Is Unlikely to survive more than 1 month under standard of care, in the opinion of the study doctor\n12. Hypersensitivity to any of the treatment drugs or excipients;\n13. If the patient is on any medicines contraindicated with the study medicines (see Appendix 3);\n14. Mentally incapacitated and no guardian able to sign on patients Clinical study protocol, version 5.0 METRICS TRIAL, Metabolic Cancer 001 5th Apr 2016 Confidential Page 5 of 65 behalf;\n15. History or presence of alcohol or substance abuse;\n16. Participation in a clinical trial of an investigational medicinal product that is viewed by the Study Physician to be a significant risk to the participant's safety;\n17. Direct employee of the study site.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}